Connor, Clark & Lunn Investment Management Ltd. Blueprint Medicines Corp Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 5,132 shares of BPMC stock, worth $464,240. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,132Holding current value
$464,240% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding BPMC
# of Institutions
351Shares Held
60.3MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$605 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$601 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.39MShares$487 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$359 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$250 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.4B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...